Last reviewed · How we verify
FMX103 minocycline foam 1.5%
FMX103 minocycline foam 1.5% is a Tetracycline antibiotic Small molecule drug developed by Vyne Therapeutics Inc.. It is currently in Phase 3 development for Acne vulgaris.
Minocycline, a tetracycline antibiotic, reduces inflammation and bacterial colonization in acne by inhibiting bacterial protein synthesis and suppressing inflammatory mediators.
Minocycline, a tetracycline antibiotic, reduces inflammation and bacterial colonization in acne by inhibiting bacterial protein synthesis and suppressing inflammatory mediators. Used for Acne vulgaris.
At a glance
| Generic name | FMX103 minocycline foam 1.5% |
|---|---|
| Sponsor | Vyne Therapeutics Inc. |
| Drug class | Tetracycline antibiotic |
| Target | Bacterial ribosome (30S subunit); also has anti-inflammatory effects on host immune mediators |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Minocycline is a broad-spectrum tetracycline antibiotic that works through multiple mechanisms relevant to acne treatment: it inhibits bacterial protein synthesis in Cutibacterium acnes (formerly Propionibacterium acnes), reducing bacterial load on the skin. Additionally, minocycline has anti-inflammatory properties independent of its antimicrobial activity, including inhibition of matrix metalloproteinases and reduction of pro-inflammatory cytokines. The foam formulation (FMX103) is designed for topical delivery to improve skin penetration and patient compliance.
Approved indications
- Acne vulgaris
Common side effects
- Application site irritation
- Erythema
- Dryness
- Photosensitivity
Key clinical trials
- A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea (PHASE3)
- A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea (PHASE3)
- A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea (PHASE3)
- Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FMX103 minocycline foam 1.5% CI brief — competitive landscape report
- FMX103 minocycline foam 1.5% updates RSS · CI watch RSS
- Vyne Therapeutics Inc. portfolio CI
Frequently asked questions about FMX103 minocycline foam 1.5%
What is FMX103 minocycline foam 1.5%?
How does FMX103 minocycline foam 1.5% work?
What is FMX103 minocycline foam 1.5% used for?
Who makes FMX103 minocycline foam 1.5%?
What drug class is FMX103 minocycline foam 1.5% in?
What development phase is FMX103 minocycline foam 1.5% in?
What are the side effects of FMX103 minocycline foam 1.5%?
What does FMX103 minocycline foam 1.5% target?
Related
- Drug class: All Tetracycline antibiotic drugs
- Target: All drugs targeting Bacterial ribosome (30S subunit); also has anti-inflammatory effects on host immune mediators
- Manufacturer: Vyne Therapeutics Inc. — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Acne vulgaris
- Compare: FMX103 minocycline foam 1.5% vs similar drugs
- Pricing: FMX103 minocycline foam 1.5% cost, discount & access